BTG1
BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.
Overview
Anti-proliferative protein.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, animal model 0.47, genetic association 0.28, somatic mutation 0.79). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.
- 1 · What it is
BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.
- 2 · What goes wrong in cancer
Anti-proliferative protein. Locus 12q21.33 (HGNC).
- 3 · How drugs use it
No product in this corpus aims at BTG1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1130 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62324 (protein name, function text, keywords and locations (REST API)); CIViC gene BTG1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000133639 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.67 (GraphQL API, CC0)); IntOGen BTG1 (driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Anti-proliferative protein. Locus 12q21.33 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.67 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (NHL)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Chronic lymphocytic leukaemia: IntOGen driver in 1 cohort (CLLSLL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"BTG1" OR ABSTRACT:"BTG1" OR TITLE:"BTG anti-proliferation factor 1" OR ABSTRACT:"BTG anti-proliferation factor 1" OR TITLE:"APRO2" OR ABSTRACT:"APRO2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BTG1, not a curated reading list.